Foetal safety of old and new antiepileptic drugs

Expert Opinion on Drug Safety

Volumn 14, Issue 10, 2015, Pages 1563-1571

  Verrotti, Alberto ^a   Mencaroni, Elisabetta ^a   Castagnino, Miriam ^a   Zaccara, Gaetano ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Florence Health Authority   (Italy)

Author keywords

antiepileptic drugs; foetal malformations; neurodevelopmental disorders; teratogenicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; TERATOGENIC AGENT;

ANTICONVULSANT THERAPY; BRAIN DEVELOPMENT; CLEFT FACE; COGNITIVE DEVELOPMENT; CONGENITAL HEART MALFORMATION; ENVIRONMENTAL EXPOSURE; FETAL HYDANTOIN SYNDROME; FETAL SAFETY; FETUS; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL MALFORMATION; HUMAN; HYPOSPADIAS; MONOTHERAPY; MOUTH MALFORMATION; NEURAL TUBE DEFECT; PREGNANCY; PRENATAL DRUG EXPOSURE; REVIEW; SAFETY; SPINAL DYSRAPHISM; SYSTEMATIC REVIEW; TERATOGENESIS; TERATOGENICITY; UROGENITAL TRACT MALFORMATION; ABNORMALITIES, DRUG-INDUCED; ANIMAL; COMPLICATION; EPILEPSY; FEMALE; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 84942292499     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1084288     Document Type: Review

References (95)

1. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother 2012; 12: 707-17
2. Kluger S, Meador K. Teratogenicity of antiepileptic drugs. Semin Neurol 2008; 328-35
3. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 993-1002
4. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-75
5. Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infance exposed to antiepileptic drugs in utero. Epilepsia 2013; 54: 165
6. Schachter SC, Yerby MS. Management of epilepsy: pharmacologic therapy and quality-of-life issues. Postgrad Med 1997; 101: 133-8
7. Tomson T, Battino D, Bonizzoni E, et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-17
8. Landmark CJ, Fossmark H, Larsson PG, et al. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011; 95: 51-9
9. Ardinger H, Atkin J, Blackston R, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171-85
10. Chevallier B, Negre V, Bidat E, Lagardere B. Fetal valproate syndrome and somatic and psychomotor development. Arch Franc Pediatr 1989; 46: 627-30
11. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995; 32: 724-7
12. Hanson JW, Myrianthopoulos NC, Sedgwick-Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediat 1976; 89: 662-8
13. Winter R, Donnai D, Burn J, Tucker S. Fetal valproate syndrome: Is there a recognisable phenotype? J Med Genet 1987; 24: 692-5
14. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia 2010; 51: 2058-65
15. Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011; 96: 643-7
16. Meador K, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New Eng J Med 2009; 360: 1597-605
17. Nadebaum C, Anderson V, Vajda F, et al. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011; 17: 133-42
18. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Eng J Med 2001; 344: 1132-8
19. Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341: c6581
20. Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011; 60: 1-70
21. Hernandez-Diaz S, Smith CR, Wyszynski DF, Holmes LB. Major malformations among infants exposed to carbamazepine during pregnancy (Teratology Society Abstracts). Birth Defects Res A Clin Mol 2007; 79: 357
22. Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006; 22: 214-26
23. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193
24. Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68: 1275-81
25. Meador KJ, Reynolds RW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81: 1-13
26. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002; 16: 9-17
27. Wide K, Henning E, Eomson T, Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002; 91: 409-14
28. Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84: 382-90
29. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014; 30: 10 CD010236
30. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87: 285-90
31. Singh R, Kumar N, Arora S, et al. Fetal hydantoin syndrome and its anaesthetic implications: A case report. Case Rep Anesthesiol 2012; 370412
32. Jones KI. SmithS recognizable patterns of human malformation. 5th edition. WB. Saunders; Philadelphia, PA, USA: 1997
33. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67: 407-12
34. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the american academy of neurology and american epilepsy society. Neurology 2009; 73: 126-32
35. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67: 407-12
36. Satgé D, Sasco AJ, Little J. Antenatal therapeutic drug exposure and fetal/neonatal tumours: review of 89 cases. Paediatr Perinat Epidemiol 1998; 12: 84-117
37. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64: 1874-8
38. Veiby G, Daltveit AK, Schjølberg S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 2013; 54: 1462-72
39. Hernández-Diáz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-14
40. Adab N, Tudur Smith C, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Data Sys Rev 2004 (Issue 3): CD004848
41. Thomas S, Ajaykumar B, Singhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008; 13: 229-36
42. Leavitt A, Yerby M, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992; 42: 141-3
43. Rovet J, Cole S, Nulman I, et al. Effects of maternal epilepsy on childrens neurodevelopment. Child Neuropsychol 1995; 1: 150-7
44. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673-8
45. Hernández-Diáz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692
46. Tica OS, Tica AA, Brailoiu CG, et al. Sirenomelia after phenobarbital and carbamazepine therapy in pregnancy. Birth Defects Res A Clin Mol Teratol 2013; 97: 425-8
47. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274: 1518-25
48. Thomas S, Sukumaran S, Lukose N, et al. Intellectual and language functions in children of mothers with epilepsy. Epilepsia 2007; 48: 2234-40
49. Vajda FJ, OBrien TJ, Lander CM, et al. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013; 54: 181-6
50. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42: 111
51. Lindhout D, Schmidt D. In utero exposure to valproate and neural-tube defects. Lancet 1986; 2: 1932
52. Kini U, Adab N, Vinten J, et al. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006; 91: F90
53. Perucca E, Tomson T. Prenatal exposure to antiepileptic drugs. Lancet 2006; 367: 1467
54. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009; 50: 2130
55. Bromfield EB, Dworetzky BA, Wyszynski DF, et al. Valproate teratogenicity and epilepsy syndrome. Epilepsia 2008; 49: 2122
56. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961
57. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362: 2185
58. Vajda FJ. Effect of anti-epileptic drug therapy on the unborn child. J Clin Neurosci 2014; 21: 716-21
59. Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005; 112: 137
60. Bavoux F, Fournier-Perhilou AI, Wood C, et al. Neonatal fibrinogen depletion caused by sodium valproate. Ann Pharmacother 1994; 28: 1307
61. Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987; 2: 740
62. Mole TB, Marson A, Appleton R. Withholding the choice of sodium valproate to young women with generalised epilepsy: are we causing more harm than good? Seizure 2015; 24: 127-30
63. Dean JCS, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children with prenatal exposure to antiepileptic drugs before birth. J Med Gen 2002; 39: 251-9
64. Bromley R. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008; 71: 1923-5
65. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010; 10: 943-59
66. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003; 4: 310-17
67. Velez-Ruiz NJ, Meador KJ. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf 2015; 3: 271-8
68. Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 2012; 94: 599-606
69. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955-60
70. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70: 2152-8
71. Dolk H, Jentink J, Loane M, et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71: 714-22
72. Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109: 9-13
73. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305: 1996-2002
74. Cunnington M, Ferber S, Quartey G. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007; 48: 1207-10
75. Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76: 1817-23
76. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80: 400-5
77. Shallcross R, Bromley R, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76: 383-9
78. Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology 2014; 82: 213-21
79. Bülau P1, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34: 311-13
80. Lutz UC, Wiatr G, Gaertner HJ, Bartels M. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol 2007; 27: 730-2
81. Lopalco A, Ali H, Denora N, Rytting E. Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. Int J Nanomedicine 2015; 10: 1985-96
82. Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicol 2012; 34: 308-11
83. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37: 1242-4
84. Lawthom C, Smith PE, Wild JM. In utero exposure to vigabatrin: no indication of visual field loss. Epilepsia 2009; 50: 318-21
85. Tran A, OMahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998; 45: 409-11
86. Sharma A, Cavitt J, Privitera M, Moseley BD. Improving the prescription of folate to women receiving antiepileptic drugs. Epilepsy Res 2015; 112: 27-30
87. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009; 80 (5): 506-11
88. Koo J, Zavras A. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral Dis 2013; 19: 712-20
89. McGrath A, Sharpe L, Lah S, Parratt K. Pregnancy-related knowledge and information needs of women with epilepsy: a systematic review. Epilepsy Behav 2014; 31: 246-55
90. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015. [Epub ahead of print]
91. Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurology 2013; 70: 1367-74
92. Vajda FJ, OBrien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs-an update. Acta Neurol Scand 2014; 130: 234-8
93. Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009; 15: 339-43
94. Fathe K, Palacios A, Finnell RH. Brief report novel mechanism for valproate-induced teratogenicity. Birth Defects Res A Clin Mol Teratol 2014; 100: 592-7
95. Tomson T, Battino D, Bonizzoni E, et al. EURAP Study Group. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology 2015. [. Epub ahead of print]